- CEO
- Akash Bedi
- Full Time Employees
- 2,800
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Address
- One Island East Quarry Bay Hong Kong
- IPO Date
- Apr 21, 2011
- Business
- Health and Happiness (H&H) International Holdings Limited is an investment holding company engaged in the manufacture and sale of premium pediatric nutrition, baby care, adult nutrition and care, and pet nutrition and care products worldwide. The company operates through three primary business segments offering infant milk formulas for infants, children, and expectant mothers under brands like Biostime; vitamins, herbal and mineral supplements, skin care, and sports nutrition products for adults under brands including Swisse and Aurelia London; probiotic and nutritional supplements for infants, children, and expectant mothers; pet food and supplements under brands such as Solid Gold Pet, Zesty Paws, and others; and additional pediatric products like dried baby food and baby care items under brands including Dodie and Good Goût. Founded in 1999 and headquartered in Quarry Bay, Hong Kong, with additional offices in locations such as London, the company conducts geographic operations across Greater China, Australia and New Zealand (ANZ), North America, Europe, Southeast Asia, and other international markets including France, the United Kingdom, the United States, Indonesia, Malaysia, Singapore, Thailand, and Vietnam. In recent developments, H&H reported revenue growth of 4.9% for the first half of 2025, driven by expansions in high-margin nutritional supplements comprising 65.6% of revenue, with strong like-for-like growth in vitamins, herbal, mineral, and sports nutrition (VHMS) at 5.8% and pet supplements at 14.3%; the company launched new higher-margin pet food and supplement products like Solid Gold fish oil supplements contributing 14.7% of pet nutrition revenue in mainland China, prioritized e-commerce channels across the UK, Europe, Asia, and ANZ, and established a partnership with Greater Good Charities in 2024 while maintaining no major acquisitions in 2024 or 2025 amid strategic focus on premium segments and refinancing efforts including RMB 1.4 billion in new term loans.